Posted on 04/20/2020 7:28:04 AM PDT by SeekAndFind
India is all set to use the most-wanted drug around the world at present backed by United States President Donald Trump, Hydroxychloroquine (HCQ), for a first-of-its-kind mass experiment on Asia’s largest slum in the national financial capital – Mumbai’s Dharavi.
After multiple cases of coronavirus were reported from Dharavi, the area was sealed and listed as a containment zone. Now, officials of the Brihanmumbai Municipal Corporation (BMC) are trying to identify a target group who will receive the anti-malarial drug as an experimental treatment for the viral infection.
According to a Bloomberg report, the officials are currently consulting medical experts on the duration of dosage and its possible side effects, based on which a decision will be taken to begin the experimentation.
The low-cost drug that was touted as a “game changer” by Donald Trump created much frenzy over the last month after it came to be one of the few reliable treatments of the gruesome disease.
Recently, India cleared the the first list of 13 countries who will get hydroxychloroquine (HCQ) in the fight against COVID-19 pandemic. These included – US, Spain, Germany, Dominican Republic, Brazil, Bahrain, Nepal, Bhutan, Afghanistan, Maldives and Bangladesh.
According to sources from the central government, India has also decided to supply the anti-malarial drug to as many as 55 countries.
(Excerpt) Read more at india.com ...
We received a large quantity of this medication. I hope it works for them. I read awhile ago that there was very real concern in a particularly impoverished area of Mumbai. I wonder of this is the one. Thank you for posting.
What the world wants to know...…
What is the covidical19 status so far in India?
559 (known) deaths. per Johns Hopkins
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.